Catalent now owns gene therapy CDMO Paragon Bioservices, and with the $1.2 billion deal it gets a new long-term manufacturing agreement with gene therapy biotech Sarepta. As part of that relationship come plans to expand manufacturing that will bring Paragon’s, and so Catalent’s, capacity to 425,000 square feet.
